207 related articles for article (PubMed ID: 27250763)
1. Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.
Pinkerneil M; Hoffmann MJ; Kohlhof H; Schulz WA; Niegisch G
Target Oncol; 2016 Dec; 11(6):783-798. PubMed ID: 27250763
[TBL] [Abstract][Full Text] [Related]
2. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms.
Pinkerneil M; Hoffmann MJ; Deenen R; Köhrer K; Arent T; Schulz WA; Niegisch G
Mol Cancer Ther; 2016 Feb; 15(2):299-312. PubMed ID: 26772204
[TBL] [Abstract][Full Text] [Related]
4. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells.
Hoffmann MJ; Meneceur S; Hommel K; Schulz WA; Niegisch G
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33670166
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.
Hölscher AS; Schulz WA; Pinkerneil M; Niegisch G; Hoffmann MJ
Clin Epigenetics; 2018; 10():1. PubMed ID: 29312470
[TBL] [Abstract][Full Text] [Related]
7. Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.
Zhijun H; Shusheng W; Han M; Jianping L; Li-Sen Q; Dechun L
Tumour Biol; 2016 Aug; 37(8):10257-67. PubMed ID: 26831668
[TBL] [Abstract][Full Text] [Related]
8. Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells.
Wobser M; Weber A; Glunz A; Tauch S; Seitz K; Butelmann T; Hesbacher S; Goebeler M; Bartz R; Kohlhof H; Schrama D; Houben R
J Hematol Oncol; 2019 Mar; 12(1):30. PubMed ID: 30885250
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment.
Lehmann M; Hoffmann MJ; Koch A; Ulrich SM; Schulz WA; Niegisch G
J Exp Clin Cancer Res; 2014 Jul; 33(1):59. PubMed ID: 25011684
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
[TBL] [Abstract][Full Text] [Related]
11. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
12. Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways.
Chen YJ; Wang WH; Wu WY; Hsu CC; Wei LR; Wang SF; Hsu YW; Liaw CC; Tsai WC
PLoS One; 2017; 12(8):e0183368. PubMed ID: 28829799
[TBL] [Abstract][Full Text] [Related]
13. HDACs and HDAC Inhibitors in Urothelial Carcinoma - Perspectives for an Antineoplastic Treatment.
Pinkerneil M; Hoffmann MJ; Schulz WA; Niegisch G
Curr Med Chem; 2017; 24(37):4151-4165. PubMed ID: 28078999
[TBL] [Abstract][Full Text] [Related]
14. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
Hayashi A; Horiuchi A; Kikuchi N; Hayashi T; Fuseya C; Suzuki A; Konishi I; Shiozawa T
Int J Cancer; 2010 Sep; 127(6):1332-46. PubMed ID: 20049841
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.
Mishra VK; Wegwitz F; Kosinsky RL; Sen M; Baumgartner R; Wulff T; Siveke JT; Schildhaus HU; Najafova Z; Kari V; Kohlhof H; Hessmann E; Johnsen SA
Nucleic Acids Res; 2017 Jun; 45(11):6334-6349. PubMed ID: 28369619
[TBL] [Abstract][Full Text] [Related]
16. 4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells.
Fu M; Wan F; Li Z; Zhang F
Biochem Biophys Res Commun; 2016 Mar; 471(2):267-73. PubMed ID: 26773495
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells.
Eto S; Saeki K; Yoshitake R; Yoshimoto S; Shinada M; Ikeda N; Kamoto S; Tanaka Y; Kato D; Maeda S; Tsuboi M; Chambers J; Uchida K; Nishimura R; Nakagawa T
PLoS One; 2019; 14(6):e0218382. PubMed ID: 31206526
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
19. Isotype-Specific Inhibition of Histone Deacetylases: Identification of Optimal Targets for Radiosensitization.
Kim JH; Moon SH; No M; Kim JJ; Choi EJ; Cho BJ; Kim JS; Kim IH; Kim IA
Cancer Res Treat; 2016 Jul; 48(3):1130-40. PubMed ID: 26582395
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer.
Wilson AJ; Byun DS; Popova N; Murray LB; L'Italien K; Sowa Y; Arango D; Velcich A; Augenlicht LH; Mariadason JM
J Biol Chem; 2006 May; 281(19):13548-13558. PubMed ID: 16533812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
